Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
NCT05135845Phase 2Suspended
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2022
- Primary completion
- Apr 2023
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capmatinib, spartalizumab in esophageal adenocarcinoma (EAC), gastric adenocarcinoma, sponsored by Assistance publique - Hôpitaux de Paris. Started Mar 2022; status: suspended.
02
Drugs
capmatinibspartalizumab
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT05135845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135845.